

Jonathan E Alpert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4470289/publications.pdf>

Version: 2024-02-01

204
papers

13,783
citations

17440

63
h-index

22832

112
g-index

214
all docs

214
docs citations

214
times ranked

10308
citing authors

#	ARTICLE	IF	CITATIONS
1	Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. <i>Contemporary Clinical Trials</i> , 2004, 25, 119-142.	1.9	898
2	Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2008, 165, 342-351.	7.2	741
3	Remissions in Maternal Depression and Child Psychopathology. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1389.	7.4	539
4	A Comparison of Lithium and T ₃ Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1519-1530.	7.2	526
5	Residual Symptoms in Depressed Patients Who Respond Acutely to Fluoxetine. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 221-225.	2.2	395
6	Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. <i>Psychological Medicine</i> , 2004, 34, 1299-1308.	4.5	352
7	Anxiety disorders in major depression. <i>Comprehensive Psychiatry</i> , 2000, 41, 97-102.	3.1	275
8	S-Adenosyl Methionine (SAME) Augmentation of Serotonin Reuptake Inhibitors for Antidepressant Nonresponders With Major Depressive Disorder: A Double-Blind, Randomized Clinical Trial. <i>American Journal of Psychiatry</i> , 2010, 167, 942-948.	7.2	275
9	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1161-1172.	7.2	233
10	Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials. <i>American Journal of Psychiatry</i> , 2012, 169, 1267-1274.	7.2	229
11	Major depressive subtypes and treatment response. <i>Biological Psychiatry</i> , 1997, 42, 568-576.	1.3	222
12	Timing of Onset of Antidepressant Response With Fluoxetine Treatment. <i>American Journal of Psychiatry</i> , 2000, 157, 1423-1428.	7.2	207
13	A Cross-Sectional Study of the Prevalence of Cognitive and Physical Symptoms During Long-Term Antidepressant Treatment. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1754-1759.	2.2	181
14	Children of Depressed Mothers 1 Year After the Initiation of Maternal Treatment: Findings From the STAR*D-Child Study. <i>American Journal of Psychiatry</i> , 2008, 165, 1136-1147.	7.2	169
15	Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine. <i>American Journal of Psychiatry</i> , 1997, 154, 1760-1762.	7.2	167
16	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006, 163, 1161.	7.2	167
17	Frontal EEG predictors of treatment outcome in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2009, 19, 772-777.	0.7	158
18	Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. <i>Acta Psychiatrica Scandinavica</i> , 2005, 112, 425-433.	4.5	157

#	ARTICLE	IF	CITATIONS
19	Role of endogenous substance P in stress-induced activation of mesocortical dopamine neurones. <i>Nature</i> , 1983, 306, 791-792.	27.8	153
20	Children of Depressed Mothers 1 Year After Remission of Maternal Depression: Findings From the STAR*D-Child Study. <i>American Journal of Psychiatry</i> , 2011, 168, 593-602.	7.2	149
21	Pharmacological approaches to the challenge of treatment-resistant depression. <i>Dialogues in Clinical Neuroscience</i> , 2015, 17, 111-126.	3.7	149
22	What Clinical and Symptom Features and Comorbid Disorders Characterize Outpatients with Anxious Major Depressive Disorder: A Replication and Extension. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 823-835.	1.9	148
23	Nutrition and Depression: The Role of Folate. <i>Nutrition Reviews</i> , 1997, 55, 145-149.	5.8	148
24	Strengthening clinical effectiveness trials: Equipoise-stratified randomization. <i>Biological Psychiatry</i> , 2001, 50, 792-801.	1.3	144
25	Nortriptyline for Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 35-39.	2.2	139
26	Nutrition and depression: focus on folate. <i>Nutrition</i> , 2000, 16, 544-546.	2.4	138
27	Ziprasidone Augmentation of Selective Serotonin Reuptake Inhibitors (SSRIs) for SSRI-Resistant Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 217-221.	2.2	127
28	Children of Currently Depressed Mothers. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 126-136.	2.2	123
29	Impairment in T-maze reinforced alternation performance following nucleus basalis magnocellularis lesions in rats. <i>Behavioural Brain Research</i> , 1984, 13, 63-70.	2.2	121
30	Factors that differentiate early vs. later onset of major depression disorder. <i>Psychiatry Research</i> , 2004, 129, 127-140.	3.3	121
31	Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. <i>Journal of Affective Disorders</i> , 2019, 243, 516-524.	4.1	120
32	A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 441-447.	1.4	116
33	Double-Blind Study of High-Dose Fluoxetine Versus Lithium or Desipramine Augmentation of Fluoxetine in Partial Responders and Nonresponders to Fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 379-387.	1.4	114
34	The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder. <i>American Journal of Psychiatry</i> , 2003, 160, 2122-2127.	7.2	109
35	Attention deficit hyperactivity disorder in childhood among adults with major depression. <i>Psychiatry Research</i> , 1996, 62, 213-219.	3.3	107
36	The effects of central catecholamine depletions on spatial learning in rats. <i>Behavioural Brain Research</i> , 1983, 9, 83-104.	2.2	104

#	ARTICLE	IF	CITATIONS
37	Personality disorders and depression. <i>Psychological Medicine</i> , 2002, 32, 1049-1057.	4.5	100
38	Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e719-e725.	2.2	100
39	Monoamine Oxidase A and Catechol-O-Methyltransferase Functional Polymorphisms and the Placebo Response in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 372-377.	1.4	98
40	S-Adenosyl-L-Methionine (SAME) as an Adjunct for Resistant Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 661-664.	1.4	97
41	Predictors of Relapse in a Prospective Study of Fluoxetine Treatment of Major Depression. <i>American Journal of Psychiatry</i> , 2006, 163, 1542-1548.	7.2	95
42	Social phobia, avoidant personality disorder and atypical depression: co-occurrence and clinical implications. <i>Psychological Medicine</i> , 1997, 27, 627-633.	4.5	92
43	Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 92-95.	1.4	90
44	Obesity among outpatients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 59-63.	2.1	89
45	Serum Folate, Vitamin B12, and Homocysteine in Major Depressive Disorder, Part 1. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1090-1095.	2.2	88
46	Folinic Acid (Leucovorin) as an Adjunctive Treatment for SSRI-Refractory Depression. <i>Annals of Clinical Psychiatry</i> , 2002, 14, 33-38.	0.6	87
47	S-adenosyl-methionine in depression: A comprehensive review of the literature. <i>Current Psychiatry Reports</i> , 2003, 5, 460-466.	4.5	87
48	Vagus Nerve Stimulation: 2-Year Outcomes for Bipolar Versus Unipolar Treatment-Resistant Depression. <i>Biological Psychiatry</i> , 2008, 64, 455-460.	1.3	83
49	Adverse Endocrine and Metabolic Effects of Psychotropic Drugs. <i>CNS Drugs</i> , 2009, 23, 1003-1021.	5.9	83
50	The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 523.	2.1	81
51	Course and Severity of Maternal Depression: Associations with Family Functioning and Child Adjustment. <i>Journal of Youth and Adolescence</i> , 2008, 37, 906-916.	3.5	81
52	Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 282-289.	4.5	81
53	Fenfluramine challenge in unipolar depression with and without anger attacks. <i>Psychiatry Research</i> , 2000, 94, 9-18.	3.3	79
54	A Double-Blind, Randomized Controlled Trial of Ethyl-Eicosapentaenoate for Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1636-1644.	2.2	79

#	ARTICLE	IF	CITATIONS
55	CCK-8 modulation of mesolimbic dopamine: Antagonism of amphetamine-stimulated behaviors. <i>Peptides</i> , 1983, 4, 749-753.	2.4	75
56	Outcome Definitions and Predictors in Depression. <i>Psychotherapy and Psychosomatics</i> , 1998, 67, 266-270.	8.8	75
57	Tryptophan depletion in SSRI-recovered depressed outpatients. <i>Psychopharmacology</i> , 2001, 155, 123-127.	3.1	75
58	A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. <i>European Neuropsychopharmacology</i> , 2008, 18, 639-645.	0.7	73
59	Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. <i>Photomedicine and Laser Surgery</i> , 2018, 36, 634-646.	2.0	73
60	Selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain by infusion of a stable substance P analogue into the ventral tegmental area. <i>Brain Research</i> , 1986, 363, 145-147.	2.2	71
61	Clinical differences among depressed patients with and without a history of suicide attempts: Findings from the STAR*D trial. <i>Journal of Affective Disorders</i> , 2007, 97, 77-84.	4.1	71
62	Effects of Adding Cognitive Therapy to Fluoxetine Dose Increase on Risk of Relapse and Residual Depressive Symptoms in Continuation Treatment of Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 474-480.	1.4	63
63	Patterns of axis I comorbidity in early-onset versus late-onset major depressive disorder. <i>Biological Psychiatry</i> , 1999, 46, 202-211.	1.3	62
64	A survey of prescribing practices in the treatment of depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 177-187.	4.8	62
65	Preadult onset vs. adult onset of major depressive disorder: a replication study. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 196-205.	4.5	62
66	Remission of Maternal Depression: Relations to Family Functioning and Youth Internalizing and Externalizing Symptoms. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2008, 37, 714-724.	3.4	60
67	Inflammatory cytokines in major depressive disorder: A case-control study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 23-31.	2.3	60
68	A Controlled Trial of Bupropion Added to Nicotine Patch and Behavioral Therapy for Smoking Cessation in Adults With Unipolar Depressive Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 660-666.	1.4	59
69	Serum Folate, Vitamin B12, and Homocysteine in Major Depressive Disorder, Part 2. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1096-1098.	2.2	59
70	Body dysmorphic disorder in outpatients with major depression. <i>Journal of Affective Disorders</i> , 2002, 69, 141-148.	4.1	57
71	Psychosocial Functioning During the Treatment of Major Depressive Disorder With Fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 507-511.	1.4	57
72	Site Versus Centralized Raters in a Clinical Depression Trial. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 193-197.	1.4	57

#	ARTICLE	IF	CITATIONS
73	Cardiovascular Risk Factors May Moderate Pharmacological Treatment Effects in Major Depressive Disorder. <i>Psychosomatic Medicine</i> , 2005, 67, 703-706.	2.0	55
74	Ethnicity/Race and Outcome in the Treatment of Depression. <i>Medical Care</i> , 2007, 45, 1043-1051.	2.4	54
75	Childhood psychopathology retrospectively assessed among adults with early onset major depression. <i>Journal of Affective Disorders</i> , 1994, 31, 165-171.	4.1	53
76	Serum cholesterol and serotonergic function in major depressive disorder. <i>Psychiatry Research</i> , 2003, 118, 137-145.	3.3	52
77	Open Study of the Catechol-O-Methyltransferase Inhibitor Tolcapone in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 329-335.	1.4	51
78	Letter to the Editor: New onset psychosis and mania following COVID-19 infection. <i>Journal of Psychiatric Research</i> , 2020, 130, 177-179.	3.1	50
79	Gender differences in Axis I comorbidity among depressed outpatients. <i>Journal of Affective Disorders</i> , 1996, 38, 129-133.	4.1	49
80	Comorbid Medical Illness and Relapse of Major Depressive Disorder in the Continuation Phase of Treatment. <i>Psychosomatics</i> , 2004, 45, 419-425.	2.5	48
81	Somatic symptoms in treatment-resistant depression. <i>Psychiatry Research</i> , 2003, 118, 39-45.	3.3	46
82	Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. <i>Annals of Clinical Psychiatry</i> , 2002, 14, 33-38.	0.6	44
83	Use of the five-factor inventory in characterizing patients with major depressive disorder. <i>Comprehensive Psychiatry</i> , 2001, 42, 488-493.	3.1	43
84	Cognitive-Behavioral Therapy for Patients With Parkinson's Disease and Comorbid Major Depressive Disorder. <i>Psychosomatics</i> , 2010, 51, 124-129.	2.5	43
85	Serum Cholesterol in Treatment-Resistant Depression. <i>Neuropsychobiology</i> , 2003, 47, 146-151.	1.9	41
86	Cognitive therapy for anxious depression in STAR*ŽD: What have we learned?. <i>Journal of Affective Disorders</i> , 2012, 142, 213-218.	4.1	41
87	Climate change and mental health research methods, gaps, and priorities: a scoping review. <i>Lancet Planetary Health</i> , The, 2022, 6, e281-e291.	11.4	41
88	Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. <i>Journal of Affective Disorders</i> , 2012, 136, 1174-1178.	4.1	40
89	The potential relationship between levels of perceived stress and subtypes of major depressive disorder (MDD). <i>Acta Psychiatrica Scandinavica</i> , 2004, 110, 465-470.	4.5	39
90	Antidepressant Effects on Emotional Temperament: Toward a Biobehavioral Research Paradigm for Major Depressive Disorder. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 441-451.	3.9	38

#	ARTICLE	IF	CITATIONS
91	Fluoxetine Treatment of Anger Attacks: A Replication Study. <i>Annals of Clinical Psychiatry</i> , 1996, 8, 7-10.	0.6	36
92	Virtual Reality, Telemedicine, Web and Data Processing Innovations in Medical and Psychiatric Education and Clinical Care. <i>Academic Psychiatry</i> , 2006, 30, 528-533.	0.9	36
93	Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 301-307.	1.8	35
94	NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients. <i>Psychiatry Research</i> , 2002, 109, 9-16.	3.3	34
95	Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. <i>Journal of Psychiatric Research</i> , 2008, 42, 134-140.	3.1	34
96	Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. <i>International Clinical Psychopharmacology</i> , 2010, 25, 214-217.	1.7	34
97	PSYCHOTHERAPEUTIC APPROACHES TO AGGRESSIVE AND VIOLENT PATIENTS. <i>Psychiatric Clinics of North America</i> , 1997, 20, 453-472.	1.3	33
98	Relationships between major depressive disorder and comorbid anxiety and personality disorders. <i>Comprehensive Psychiatry</i> , 2005, 46, 266-271.	3.1	32
99	Axis I and Axis II disorder comorbidity in unipolar depression with anger attacks. <i>Journal of Affective Disorders</i> , 1999, 52, 217-223.	4.1	30
100	Major Depressive Disorder and Comorbid Cardiac Disease: Is There a Depressive Subtype With Greater Cardiovascular Morbidity? Results From the STAR*D Study. <i>Psychosomatics</i> , 2007, 48, 418-425.	2.5	30
101	A Pilot, Randomized Controlled Study of Tai Chi With Passive and Active Controls in the Treatment of Depressed Chinese Americans. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e522-e528.	2.2	30
102	Somatic Symptoms as Predictors of Time to Onset of Response to Fluoxetine in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 543-546.	2.2	30
103	Psychosocial functioning in patients with treatment resistant depression. <i>European Psychiatry</i> , 2004, 19, 196-201.	0.2	29
104	Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine. <i>Psychological Medicine</i> , 2004, 34, 555-561.	4.5	29
105	Anger Attacks in Major Depressive Disorder and Serum Levels of Homocysteine. <i>Biological Psychiatry</i> , 2006, 60, 270-274.	1.3	29
106	Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2008, 117, 271-276.	4.5	29
107	SAMe and sexual functioning. <i>European Psychiatry</i> , 2012, 27, 451-454.	0.2	29
108	Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I). <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 291-299.	1.8	28

#	ARTICLE	IF	CITATIONS
109	Remission of maternal depression and child symptoms among single mothers. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2007, 42, 962-971.	3.1	28
110	Hostility changes following antidepressant treatment: Relationship to stress and negative thinking. <i>Journal of Psychiatric Research</i> , 1996, 30, 459-467.	3.1	27
111	Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. <i>Psychiatry Research</i> , 2007, 149, 195-200.	3.3	27
112	Reliability and validity of the Symptoms of Depression Questionnaire (SDQ). <i>CNS Spectrums</i> , 2014, 19, 535-546.	1.2	27
113	Bioavailability of S-Adenosyl Methionine and Impact on Response in a Randomized, Double-Blind, Placebo-Controlled Trial in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 843-848.	2.2	27
114	Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression. <i>Journal of Psychosomatic Research</i> , 2000, 49, 183-187.	2.6	26
115	Axis III disorders in treatment-resistant major depressive disorder. <i>Psychiatry Research</i> , 2003, 118, 183-188.	3.3	26
116	The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. <i>International Clinical Psychopharmacology</i> , 2005, 20, 87-91.	1.7	26
117	Depression Outcomes of Spanish- and English-Speaking Hispanic Outpatients in STAR*D. <i>Psychiatric Services</i> , 2008, 59, 1273-1284.	2.0	26
118	Are study dropouts different from completers?. <i>Biological Psychiatry</i> , 1996, 40, 668-670.	1.3	25
119	Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients With Treatment-Resistant Depression. <i>Psychosomatics</i> , 2004, 45, 224-229.	2.5	25
120	Management of Major Depression in the Primary Care Setting. <i>Psychotherapy and Psychosomatics</i> , 2001, 70, 103-107.	8.8	24
121	A Randomized Controlled Pilot Study on Mindfulness-Based Cognitive Therapy for Unipolar Depression in Patients With Chronic Pain. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 26-34.	2.2	23
122	The Effectiveness of Telepsychiatry-Based Culturally Sensitive Collaborative Treatment for Depressed Chinese American Immigrants. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e996-e1002.	2.2	23
123	Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. <i>Acta Psychiatrica Scandinavica</i> , 2003, 108, 432-438.	4.5	22
124	Somatic Symptoms in Outpatients With Major Depressive Disorder Treated With Fluoxetine. <i>Psychosomatics</i> , 2006, 47, 348-352.	2.5	21
125	Enrolling research subjects from clinical practice: Ethical and procedural issues in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. <i>Psychiatry Research</i> , 2006, 141, 193-200.	3.3	21
126	Behavioral and Emotional Disturbances in the Offspring of Depressed Parents with Anger Attacks. <i>Psychotherapy and Psychosomatics</i> , 2003, 72, 102-106.	8.8	20

#	ARTICLE	IF	CITATIONS
127	Hopelessness as a Predictor of Non-Response to Fluoxetine in Major Depressive Disorder. <i>Annals of Clinical Psychiatry</i> , 2007, 19, 5-8.	0.6	20
128	Enhanced norepinephrine output during long-term desipramine treatment: A possible role for the extraneuronal monoamine transporter (SLC22A3). <i>Journal of Psychiatric Research</i> , 2008, 42, 605-611.	3.1	20
129	Obsessive-Compulsive Symptoms as a Risk Factor for Suicidality in U.S. College Students. <i>Journal of Adolescent Health</i> , 2016, 58, 481-484.	2.5	20
130	Gepirone Extended-Release Treatment of Anxious Depression. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1069-1075.	2.2	20
131	Signal Transduction by Platelet Adenylate Cyclase: Alterations in Depressed Patients May Reflect Impairment in the Coordinated Integration of Cellular Signals (Coincidence Detection) 11This work was presented in part at the Annual Meeting of the American Psychiatric Association, New York, NY, May 7, 1996.. <i>Biological Psychiatry</i> , 1998, 43, 574-583.	1.3	19
132	Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. <i>Psychiatry Research</i> , 2004, 126, 287-290.	3.3	19
133	The Role of Anger/Hostility in Treatment-Resistant Depression. <i>Journal of Nervous and Mental Disease</i> , 2015, 203, 762-768.	1.0	19
134	Outcomes of an online computerized cognitive behavioral treatment program for treating chinese patients with depression: A pilot study. <i>Asian Journal of Psychiatry</i> , 2018, 38, 102-107.	2.0	19
135	The Overlap Between Personality Disorders and Major Depressive Disorder (MDD). <i>Annals of Clinical Psychiatry</i> , 2004, 16, 217-224.	0.6	19
136	Association Between Stigma and Depression Outcomes Among Chinese Immigrants in a Primary Care Setting. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1287-e1292.	2.2	19
137	DEPRESSIVE BREAKTHROUGH. <i>Psychiatric Clinics of North America</i> , 2000, 23, 731-742.	1.3	18
138	Melancholia and axis II comorbidity. <i>Comprehensive Psychiatry</i> , 2002, 43, 331-335.	3.1	18
139	Amphetamine and maternal behavior: Dose response relationships. <i>Psychopharmacology</i> , 1980, 70, 195-199.	3.1	17
140	Dopamine denervation of frontal cortex or nucleus accumbens does not affect acth-induced grooming behaviour. <i>Behavioural Brain Research</i> , 1984, 12, 307-315.	2.2	17
141	Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD. <i>Depression and Anxiety</i> , 2007, 24, 433-439.	4.1	17
142	Major Depressive Disorder with Anger Attacks and Cardiovascular Risk Factors. <i>International Journal of Psychiatry in Medicine</i> , 2007, 37, 99-111.	1.8	16
143	Family history of completed suicide and characteristics of major depressive disorder: A STARŽD (sequenced treatment alternatives to relieve depression) study. <i>Journal of Affective Disorders</i> , 2008, 108, 129-134.	4.1	16
144	Assessing anxious features in depressed outpatients. <i>International Journal of Methods in Psychiatric Research</i> , 2011, 20, e69-82.	2.1	16

#	ARTICLE	IF	CITATIONS
145	Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. <i>Comprehensive Psychiatry</i> , 2003, 44, 44-50.	3.1	15
146	Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. <i>CNS Spectrums</i> , 2012, 17, 76-86.	1.2	15
147	Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 215-221.	2.1	14
148	Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. <i>European Psychiatry</i> , 2012, 27, 518-521.	0.2	14
149	PREDICTORS OF STABLE PERSONALITY DISORDER DIAGNOSES IN OUTPATIENTS WITH REMITTED DEPRESSION. <i>Journal of Nervous and Mental Disease</i> , 2002, 190, 248-256.	1.0	13
150	Teaching ethics of psychopharmacology research in psychiatric residency training programs. <i>Psychopharmacology</i> , 2003, 171, 105-111.	3.1	13
151	The Effects of Tai Chi on Sleep Quality in Chinese American Patients With Major Depressive Disorder: A Pilot Study. <i>Behavioral Sleep Medicine</i> , 2018, 16, 398-411.	2.1	13
152	Depression Treatment Expenditures for Adults in the USA: a Systematic Review. <i>Current Psychiatry Reports</i> , 2019, 21, 105.	4.5	13
153	T3 Blood Levels and Treatment Outcome in Depression. <i>International Journal of Psychiatry in Medicine</i> , 2001, 31, 367-373.	1.8	12
154	Outcomes of Recognizing Depressed Chinese American Patients in Primary Care. <i>International Journal of Psychiatry in Medicine</i> , 2005, 35, 213-224.	1.8	12
155	Does Psychiatry Residency Training Reflect the "Real World" of Psychiatry Practice? A Survey of Residency Graduates. <i>Academic Psychiatry</i> , 2007, 31, 281-289.	0.9	12
156	An Approach to the Psychopharmacologic Care of Patients: Antidepressants, Antipsychotics, Anxiolytics, Mood Stabilizers, and Natural Remedies. <i>Medical Clinics of North America</i> , 2010, 94, 1141-1160.	2.5	11
157	A Bronx tale: Exposure, containment and care on inpatient psychiatry units during COVID-19. <i>General Hospital Psychiatry</i> , 2021, 69, 121-123.	2.4	11
158	Serum Cholesterol in the Continuation Phase of Pharmacotherapy With Fluoxetine in Remitted Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 467-469.	1.4	10
159	Factors Associated with Concomitant Psychotropic Drug Use in the Treatment of Major Depression: A STAR*D Report. <i>CNS Spectrums</i> , 2009, 14, 487-498.	1.2	10
160	Interprofessional Differences in Disposition Decisions: Results From a Standardized Web-Based Patient Assessment. <i>Psychiatric Services</i> , 2013, 64, 808-811.	2.0	9
161	Personality Disorders and the Tridimensional Personality Questionnaire Factors in Major Depressive Disorder. <i>Journal of Nervous and Mental Disease</i> , 2005, 193, 747-750.	1.0	8
162	Psychiatric OSCE Performance of Students With and Without a Previous Core Psychiatry Clerkship. <i>Academic Psychiatry</i> , 2010, 34, 141-144.	0.9	8

#	ARTICLE	IF	CITATIONS
163	Increased GsM± within blood cell membrane lipid microdomains in some depressive disorders: An exploratory study. <i>Journal of Psychiatric Research</i> , 2013, 47, 706-711.	3.1	8
164	Connection During COVID-19: Pilot Study of a Telehealth Group Parenting Intervention. <i>American Journal of Psychotherapy</i> , 2022, 75, 67-74.	1.2	8
165	Maternal care received by rat pups treated with 6-hydroxydopamine. <i>Physiology and Behavior</i> , 1979, 22, 69-75.	2.1	7
166	Getting Our Own House in Order: Improving Psychiatry Education to Medical Students as a Prelude to Medical School Education Reform. <i>Academic Psychiatry</i> , 2006, 30, 170-173.	0.9	6
167	Pattern of Depressive Symptoms in Parkinson's Disease. <i>Psychosomatics</i> , 2009, 50, 448-454.	2.5	6
168	A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. <i>International Clinical Psychopharmacology</i> , 2003, 18, 293-296.	1.7	5
169	Aversive effects of subcutaneously injected vasopressin in the rat: independence of the ascending dorsal noradrenergic bundle. <i>Brain Research</i> , 1985, 337, 133-137.	2.2	4
170	Treatment-Related Adverse Events and Outcome in a Clinical Trial of Fluoxetine for Major Depressive Disorder. <i>Annals of Clinical Psychiatry</i> , 2003, 15, 187-192.	0.6	4
171	Improving depression outcome: new concepts, strategies and technologies. <i>Journal of Psychopharmacology</i> , 2006, 20, 3-4.	4.0	3
172	Conditional Probability of Response or Nonresponse of Placebo Compared With Antidepressants or St John's Wort in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 827-830.	1.4	3
173	A survey of five antidepressant properties influencing clinician's treatment choices in MDD. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 169-172.	2.2	3
174	Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1069-75.	2.2	3
175	Psychiatric comorbidity in treatment-resistant depression. , 2001, , 430-478.		2
176	Early-onset depression and the emotional and behavioral characteristics of offspring. <i>Depression and Anxiety</i> , 2003, 18, 104-108.	4.1	2
177	Treatment-Related Adverse Events and Outcome in a Clinical Trial of Fluoxetine for Major Depressive Disorder. <i>Annals of Clinical Psychiatry</i> , 2003, 15, 187-192.	0.6	2
178	How to Get Help With Starting Your Research Project: ADMSEP Task Force on Research and Scholarship. <i>Academic Psychiatry</i> , 2013, 37, 221.	0.9	2
179	The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder. <i>Focus (American Journal of Psychiatry)</i> , 2008, 116, 1084-1091.	1.0	1
180	Treatment Outcome in Depressed Latinos Predicted by Concomitant Psychosislike Symptoms. <i>Journal of Nervous and Mental Disease</i> , 2015, 203, 769-773.	1.0	1

#	ARTICLE	IF	CITATIONS
181	Geriatric Psychopharmacology: Pharmacokinetic and Pharmacodynamic Considerations. <i>Psychiatric Annals</i> , 2015, 45, .	0.1	1
182	Psychopharmacologic Issues in the Medical Setting. , 2004, , 231-267.		1
183	Mobilizing a psychiatric crisis response to COVID-19 for NYC hospital workers: Lessons learned from the mental health front lines. <i>General Hospital Psychiatry</i> , 2022, 74, 141-143.	2.4	1
184	Reply to Comments by Drs. Bschor and Bauer. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 241-242.	1.4	0
185	A Survey of Antidepressant Prescribing Practices in Major Depression with Comorbid Attention-Deficit Hyperactivity Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 216-218.	1.4	0
186	Antecedentes familiares de suicidio consumado y características del trastorno depresivo mayor: estudio STAR*D (sequenced treatment alternatives to relieve depression). <i>Psiquiatria Biologica</i> , 2008, 15, 195-201.	0.1	0
187	Stretching beyond the evidence base. <i>Bipolar Disorders</i> , 2020, 22, 418-419.	1.9	0
188	A vote for the full ticket. <i>Bipolar Disorders</i> , 2021, 23, 88-89.	1.9	0
189	Psychopharmacology and Neurotherapeutics. , 2021, , 342-388.		0
190	Disorders Related to Stress and Trauma. , 2021, , 166-178.		0
191	Feeding and Eating Disorders. , 2021, , 289-317.		0
192	Health Policy and Population Health in Behavioral Health Care in the United States. , 2021, , 473-485.		0
193	Psychosocial Interventions. , 2021, , 389-414.		0
194	Neurocognitive Disorders. , 2021, , 263-288.		0
195	Introduction to the Patient Interview. , 2021, , 38-69.		0
196	Global Health and Mental Health Care Delivery in Low-Resource Settings. , 2021, , 486-496.		0
197	Child Psychiatry and Neurodevelopmental Disorders. , 2021, , 318-328.		0
198	Psychiatry of Gender and Sexuality. , 2021, , 448-472.		0

#	ARTICLE	IF	CITATIONS
199	Obsessive-Compulsive and Related Disorders. , 2021, , 146-165.		0
200	Psychiatric Evaluation in the Medical Setting. , 2021, , 415-447.		0
201	Schizophrenia Spectrum and Other Psychotic Disorders. , 2021, , 102-127.		0
202	Clinical Neuroscience. , 2021, , 9-37.		0
203	Funcionamiento psicosocial en pacientes con depresi3n resistente al tratamiento. European Psychiatry (Ed Espa±ola), 2004, 11, 508-513.	0.0	0
204	Ethical and Safe Discharges from Psychiatric Units during the COVID-19 Pandemic.. Journal of the American Academy of Psychiatry and the Law, 2022, , .	0.2	0